摘要
There is a significant immune response to ischemia-reperfusion injury (IRI), but the role of immunomodulatory natural killer T (NKT) cell subtypes is not well understood. Here, we compared the severity of IRI in mice deficient in type I/II NKT cells (CD1d(-/-)) or type I NKT cells (J alpha 18(-/-)). The absence of NKT cells, especially type II NKT cells, accentuated the severity of renal injury, whereas repletion of NKT cells attenuated injury. Adoptively transferred NKT cells trafficked into the tubulointerstitium, which is the primary area of injury. Sulfatide-induced activation of type II NKT cells protected kidneys from IRI, but inhibition of NKT cell recruitment enhanced injury. In co-culture experiments, sulfatide-induced activation of NKT cells from either mice or humans attenuated apoptosis of renal tubular cells after transient hypoxia via hypoxia-inducible factor (HIF)-1 alpha and IL-10 pathways. Renal tissue of patients with acute tubular necrosis (ATN) frequently contained NKT cells, and the number of these cells tended to negatively correlate with ATN severity. In summary, sulfatide-reactive type II NKT cells are renoprotective in IRI, suggesting that pharmacologic modulation of NKT cells may protect against ischemic injury.
学科与关键词
- IKK1 aggravates ischemia-reperfusion kidney injury by promoting the differentiation of effector T cellsSong, Ning; Xu, Yang; Paust, Hans-Joachim; Panzer, Ulf; de las Noriega, Maria Mercedes; Guo, Linlin; Renne, Thomas; Huang, Jiabin; Meng, Xianglin; Zhao, Mingyan*; Thaiss, Friedrich*Cellular and Molecular Life Sciences, 2023, 80(5): 125.
- CYCLIN D1 AMELIORATES ISCHEMIA/REPERFUSION-INDUCED ACUTE KIDNEY INJURYHuang, Yuliang; Chen, Junzhe; Shao, Xiaofei; Li, Jinxiang; Tang, Ying60th ERA Congress, Milan, ITALY, 2023-06-15 To 2023-06-18.
- NFAT inhibitor 11R-VIVIT ameliorates mouse renal fibrosis after ischemia-reperfusion-induced acute kidney injuryXie, Zhi-yong; Dong, Wei; Zhang, Li; Wang, Meng-jie; Xiao, Zhen-meng; Zhang, Yu-hua; Shi, Wan-xin; Huang, Ying; Yang, Yan; Li, Cui-li; Fu, Lei; Zhao, Xing-chen; Li, Rui-zhao; Li, Zhi-lian; Chen, Yuan-han; Ye, Zhi-ming; Liu, Shuang-xin; Dong, Zheng; Liang, Xin-ling*Acta Pharmacologica Sinica, 2022, 43(8): 2081-2093.被引 7
